LONDON, December 15, 2014 /PRNewswire/ --
Register Now via http://bit.ly/ag8Sypm14en
On February 19th and 20th all Accredited Pharmacy Patient Medication Record Companies are invited to attend the 2015 AEGATE SAFE MEDICINE ECOSYSTEM PARTNER PROGRAM™ in Amsterdam.
The Symposium is designed to address the opportunity for the Aegate PMR Service Provider community to discover the profitable new business services that are enabled for pharmacies and the pharmacy value chain.
The Symposium Agenda: the Digital Medicine Network
- The Falsified Medicine Directive in the EU
- Value creation opportunities for PMRs
- Case Studies
- Oxford Research Program
- Enhancing the role of the Pharmacy in Health Care Delivery
- New services to Pharmaceutical Companies
- The power of the EUROPE-WIDE community of PMR Service Providers
- Cross European Linkages
- Exchange Forum: ideas for growth
- Growing the industry
- Beyond Europe
About the EU Falsified Medicines Directive
European legislation passed in 2011 and aimed at stemming the flow of falsified medicines reaching the open market within the European Economic area, the EU Falsified Medicines Directive (FMD 2011/62/EU) will, within a few years, completely change the landscape of the European pharmaceutical business model. The scope of the Directive places new obligations on all branches of the industry - manufacturers, generics producers, contract packers, re-packers and importers - amongst which is the unique identification of products at unit of sale level.
With a documented history of some 3 billion medicines scanned to date with an average rate of 200k transactions per hour across 15k dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meets the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices in Belgium, Italy, Switzerland and the UK. Our mission is to protect patients from falsified, recalled or expired medicines.
We operate a highly secure real-time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.
For more information on Aegate, please visit http://www.aegate.com
Media contact information:
Commercial Director Aegate Ltd
Cambridge Technology Centre
Melbourn SG8 6DP UK